Angion Biomedica Corp Ordinary Shares (NASDAQ:ANGN)

North American company
add to virtual portfolio
This share can be held in
Trading AccountISAJISASIPP

Share Price Chart

- Chart currently unavailable -

Market Info - ANGN

  • Market Open Price0.00
  • Previous Close0.00
  • Volume-
  • 52w Low/High-
  • Last Trade Price0.00
  • Bid/Ask Price0.00

Company Info - ANGN

  • Market Cap$404.610m
  • IndustryHealthcare
  • SectorBiotechnology
  • Currency
  • ISINUS03476J1079

Company Profile

Angion Biomedica Corp is a late-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases. Its product candidate, ANG-3777, is a hepatocyte growth factor (HGF) mimetic that is evaluating in multiple acute organ injuries and related indications, including acute kidney injury (AKI) and injuries to other major organs, such as the lungs, central nervous system (CNS) and heart; acute lung injury (ALI), with primary focus on acute respiratory distress syndrome (ARDS), and acute CNS injuries. It is advancing multiple programs for the treatment of fibrotic diseases, leading with ANG-3070, a tyrosine kinase inhibitor (TKI), and inhibitor of rho kinase 2 (ROCK2).Angion Biomedica Corp is a clinical stage biopharmaceutical company. The Company discovers and develops novel therapeutic agents to treat acute and chronic organ injury by harnessing the body's protective, reparative and regenerative systems.

Latest ANGN news

Currently there for this company. Visit our news hub for other news .